VideoHIV10th APACC 2025Abstract #34 Week 96 Results from Dolutegravir/ Lamivudine Versus Bictegravir/ Emtricitabine/Tenofovir Alafenamide Fumarate: Real-World Assessment of Weight Gain in People Living with HIV of Asian OrigiN (DRAGON) - Chien-Yu ChengView Video
VideoHIV10th APACC 2025Abstract #33 Twelve-Month (12M) Effectiveness and Safety of Bictegravir/Emtricitabine/ Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People with HIV: A Pooled Analysis from Observational Cohort Studies Across Asia - Rumi MinamiView Video
VideoHIV10th APACC 2025Abstract #36 Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes Beyond 124 Weeks in Participants Identifying as Asian - Jun Yong ChoiView Video
VideoHIV10th APACC 2025Abstract #32 Informing the Design of Future PrEP Strategies for MSM in Taiwan: A Bayesian Discrete Choice Experiment Analysis - Joyce Huei-Jiuan WuView Video
VideoHIV10th APACC 2025Abstract #31 Expanding Access to Oral HIV Pre-Exposure Prophylaxis (PrEP): Implementation Outcomes of a Pharmacy-Led PrEP Service Delivery Model in Malaysia - Yan Nee GanView Video
VideoHIV10th APACC 2025Abstract #30 Improving Mental Health of People Living with HIV Through a Community-Based Antiretroviral Delivery: A Quasi-Experimental Study in Cambodia - Sovannary TuotView Video
VideoHIV10th APACC 2025Abstract #29 Cost-Effectiveness of Rapid Versus Delayed ART Initiation in Japan: A Markov Modeling Analysis - Toshibumi TaniguchiView Video
VideoHIV10th APACC 2025Meeting People Where They Are: Implementation Research for More Responsive Health Services - Elvin H. Geng, MD, MPHView Video
Abstract10th APACC 2025(Abstract) #39 Data from the Positive Perspectives 3 Study Highlights the Continued Need for Expansion of Awareness, Belief and Confidence in Undetectable Equals Untransmittable (U=U) View Abstract
Abstract10th APACC 2025(Abstract) #38 Building Inclusive Healthcare: Tackling HIV-Related Stigma and Discrimination in Malaysian Primary Care ClinicsView Abstract
Abstract10th APACC 2025(Abstract) #37 Low Levels of Awareness of Undetectable=Untransmittable among MSM in Five Asian Countries: Results from the Asia Pacific MSM Internet SurveyView Abstract
Abstract10th APACC 2025(Abstract) #36 Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes Beyond 124 Weeks in Participants Identifying as AsianView Abstract
